Nonalcoholic steatohepatitis (NASH)

Publishing Date : February, 2017
Report Code : HCMD106
Price:
Single license $3,600
Site license $5,400
Global license $7,200


“Non-alcoholic steatohepataitis (NASH) Pipeline Analysis” gives comprehensive insights on the various drugs being developed for the treatment of NASH. The report covers all the drugs that are in various phases of development (Discovery, Preclinical & Clinical). The pipeline focuses on novel pharmacologic drugs & regenerative medicines covering small molecules, antibodies, stem cell therapies, recombinant proteins and RNA-based therapeutics, but excludes symptom relief drugs, generic combinations and supplemental drugs. The report also covers some of the hot targets in research for NASH treatments and NASH related biomarkers.

This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Non-alcoholic steatohepataitis (NASH) drugs market. The report also provides strategic insights on some of the molecules that are yet to be launched in the next few years.

 

  • 1     REPORT DESCRIPTION
  • 2     INTRODUCTION
    • 2.1     Causes & Symptoms
    • 2.2     Diagnosis
    • 2.3     Unmet needs
    • 2.4     Current therapies
  • 3     HOT TARGETS, MECHANISMS & THERAPIES
    • 3.1     Novel Disease mechanisms & therapies
    • 3.2     Leading targets of NASH
    • 3.3     Novel targets of NASH
    • 3.4     NASH biomarkers
    • 3.5     Genes Involved in NASH
  • 4     MARKET DATA
    • 4.1     Forecasting model
    • 4.2     Market dynamics
    • 4.3     Market sizing
    • 4.4     NASH Deals
    • 4.5     Funding Scenario
  • 5     PIPELINE ANALYSIS
    • 5.1     Development stage
    • 5.2     Leading players
    • 5.3     Therapeutic segmentation
    • 5.4     Target analysis
    • 5.5     Clinical update on phase3 molecules
    • 5.6     Innovative approaches
  • 6     SMALL MOLECULES
    • 6.1     Pipeline
    • 6.2     Competitive Analysis
  • 7     LARGE MOLECULE
    • 7.1     Competitive Analysis
  • 8     RNA-BASED THERAPY
    • 8.1     Pipeline
    • 8.2     Competitive Analysis
  • 9     RECOMBINANT PROTEINS
    • 9.1     Pipeline
    • 9.2     Competitive Analysis
  • 10     ANTIBODIES
    • 10.1     Pipeline
    • 10.2     Competitive Analysis
  • 11     LARGE MOLECULES (UNSPECIFIED)
    • 11.1     Pipeline
  • 12     OTHER MOLECULES
    • 12.1     Pipeline
  • 13     NASH DRUG ANALYSIS BASED ON MECHANSIMS
  • 14     MAJOR PLAYERS
    • 14.1     Company Profiles
    • 14.2     Overview
    • 14.3     Pipeline
    • 14.4     Deals
  • 15     REFERENCES

SOME OF THE COMPANIES MENTIONED

  • 1     AVOLYNT, INC
  • 2     GALECTIN THERAPEUTICS
  • 3     GALMED PHARMACEUTICALS
  • 4     GENFIT
  • 5     GILEAD SCIENCES
  • 6     INTERCEPT PHARMACEUTICALS, INC
  • 7     INVENTIVA PHARMA
  • 8     TOBIRA THERAPEUTICS